TapewireFind a company

person · Reporting owner

Weiner David B.

Disclosed activity across 1 company

Tapewire entity
45394
SEC CIK
0001669080

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
INOVIO PHARMACEUTICALS, INC.INO · Entity 6589DirectorMay 20, 2026May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

INOVIO PHARMACEUTICALS, INC.

Report date May 20, 2026 · Filed May 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-05-20Direct41,800 Reported balance After 2026-05-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-05-20 · Grant · Acquired 41,800 · Balance 41,800

F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F2: Options to vest 100% on May 20, 2027.

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect34,200 Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-05-20 · Grant · Acquired 34,200 · Balance 34,200

F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

Filing footnotes · ownership attribution and instrument terms

F1: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F2: Options to vest 100% on May 20, 2027.

F3: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 20, 2026 Filed May 21, 2026 20:11 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 34,200 $0.00 $0.00
Disclosure

SEC source: 0001669080-26-000003 · wk-form4_1779394282.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,200

Underlying: Common Stock · 34,200 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.

Read SEC document
May 20, 2026 Filed May 21, 2026 20:11 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Options · Derivative 41,800 $0.00 Strike: $1.23 $0.00
Disclosure

SEC source: 0001669080-26-000003 · wk-form4_1779394282.xml · derivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,800

Underlying: Common Stock · 41,800 shares

Expires 2036-05-20

F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: Options to vest 100% on May 20, 2027.

Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:44 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001669080-26-000002 · wk-form4_1772228657.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:44 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001669080-26-000002 · wk-form4_1772228657.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,592

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
May 21, 2025 Filed May 21, 2025 20:57 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 2,167 $0.00 $0.00
Disclosure

SEC source: 0001055726-25-000032 · wk-form4_1747861024.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,167 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025.

Read SEC document
May 21, 2025 Filed May 21, 2025 20:57 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 2,167 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-25-000032 · wk-form4_1747861024.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,620

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025.

Read SEC document
February 26, 2025 Filed Feb 28, 2025 23:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 972

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2025 Filed Feb 28, 2025 23:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2025 Filed Feb 28, 2025 23:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,453

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2025 Filed Feb 28, 2025 23:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-25-000001 · wk-form4_1740783911.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,481

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares vested on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
May 21, 2024 Filed May 22, 2024 20:51 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 2,167 $0.00 $0.00
Disclosure

SEC source: 0001055726-24-000038 · wk-form4_1716411039.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,167

Underlying: Common Stock · 2,167 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025.

F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025.

Read SEC document
May 21, 2024 Filed May 22, 2024 20:51 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Options · Derivative 2,917 $0.00 Strike: $10.99 $0.00
Disclosure

SEC source: 0001055726-24-000038 · wk-form4_1716411039.xml · derivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,917

Underlying: Common Stock · 2,917 shares

Expires 2034-05-21

F1 · shares: This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F2 · derivative.exercise_date: Options to vest 100% on May 21, 2025.

Read SEC document
May 15, 2024 Filed May 16, 2024 21:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 2,166 $0.00 $0.00
Disclosure

SEC source: 0001055726-24-000028 · wk-form4_1715893516.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,166 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
May 15, 2024 Filed May 16, 2024 21:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 2,166 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-24-000028 · wk-form4_1715893516.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,509

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 15, 2024.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 6

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,944

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 5

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 972

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 972 $0.00 $0.00
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.

F2 · shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.

F2 · derivative.underlying_shares: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,343

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2024; 972 shares will vest on February 26, 2025; and 972 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units is as follows: 972 shares vested on February 26, 2023; 972 shares vested on February 26, 2024; and 972 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2024 Filed Feb 28, 2024 22:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 972 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-24-000006 · wk-form4_1709158215.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,399

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units was as follows: 972 shares vested on February 26, 2022; 972 shares vested on February 26, 2023; and 972 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.

F2 · balance_after: Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.

Read SEC document
May 16, 2023 Filed May 16, 2023 20:54 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023.

Read SEC document
May 16, 2023 Filed May 16, 2023 20:54 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 19,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 929,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023.

Read SEC document
May 15, 2023 Filed May 16, 2023 20:54 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 26,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,000

Underlying: Common Stock · 26,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024.

F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024.

F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024.

Read SEC document
May 15, 2023 Filed May 16, 2023 20:54 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Options · Derivative 35,000 $0.00 Strike: $0.77 $0.00
Disclosure

SEC source: 0001055726-23-000037 · wk-form4_1684270484.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2033-05-15

F2 · shares: This grant was made under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.

F3 · derivative.exercise_date: Options to vest 100% on May 15, 2024.

Read SEC document
March 13, 2023 Filed Mar 13, 2023 21:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 5,833 $1.15 $6,707.95
Disclosure

SEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 910,124

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022.

Read SEC document
March 11, 2023 Filed Mar 13, 2023 21:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 11,666 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
March 11, 2023 Filed Mar 13, 2023 21:10 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-23-000014 · wf-form4_167874179632291.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 915,957

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On March 11, 2020, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; and 11,666 shares vested on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 27, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 35,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 7

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires not disclosed

F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 27, 2023, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares will vest on February 26, 2024; 11,667 shares will vest on February 26, 2025; and 11,666 shares will vest on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 27, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Option · Derivative 60,000 $0.00 Strike: $1.24 $0.00
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 6

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-02-27

F4 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 27, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025; and 15,000 shares will vest on February 26, 2026.

Read SEC document
February 27, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 11,668 $1.28 $14,935.04
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904,291

F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 13, 2022.

Read SEC document
February 26, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 11,667 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 5

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,333

Underlying: Common Stock · 11,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 11,667 $0.00 $0.00
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,666

Underlying: Common Stock · 11,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,667 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 915,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2023 Filed Feb 28, 2023 22:40 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,667 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-23-000004 · wf-form4_167762396172703.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904,292

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
August 11, 2022 Filed Aug 11, 2022 20:15 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock Option · Derivative 11,875 $0.00 Strike: $2.16 $0.00
Disclosure

SEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,875

Underlying: Common Stock · 11,875 shares

Expires 2023-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.

F3 · shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.

F3 · derivative.underlying_shares: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.

F3 · balance_after: Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.

Read SEC document
August 11, 2022 Filed Aug 11, 2022 20:15 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 11,875 $2.66 $31,587.50
Disclosure

SEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 892,625

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: These transactions were executed in multiple trades at prices ranging from $2.66 to $2.69, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Read SEC document
August 11, 2022 Filed Aug 11, 2022 20:15 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,875 $2.16 $25,650.00
Disclosure

SEC source: 0001055726-22-000050 · wf-form4_166024891625374.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 904,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 16, 2022 Filed May 17, 2022 20:32 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Options · Derivative 28,000 $0.00 Strike: $1.89 $0.00
Disclosure

SEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 5

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2032-05-16

F4 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy.

F5 · derivative.exercise_date: Options to vest 100% on May 16, 2023.

Read SEC document
May 16, 2022 Filed May 17, 2022 20:32 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 19,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023.

F4 · shares: This grant was made pursuant to the issuer's non-employee director compensation policy.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023.

Read SEC document
May 16, 2022 Filed May 17, 2022 20:32 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 9,000 $1.95 $17,550.00
Disclosure

SEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 892,625

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.

Read SEC document
May 13, 2022 Filed May 17, 2022 20:32 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 18,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 18,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022.

Read SEC document
May 13, 2022 Filed May 17, 2022 20:32 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 18,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-22-000041 · wf-form4_165281944451001.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022.

Read SEC document
March 14, 2022 Filed Mar 14, 2022 20:41 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 4,083 $3.20 $13,065.60
Disclosure

SEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 883,625

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.

F3 · price: These transactions were executed in multiple trades at prices ranging from $3.19 to $3.23, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 20:41 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 11,667 $0.00 $0.00
Disclosure

SEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,666

Underlying: Common Stock · 11,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
March 11, 2022 Filed Mar 14, 2022 20:41 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,667 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-22-000021 · wf-form4_164729029489063.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 887,708

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 11, 2021; 11,667 shares vested on March 11, 2022; 11,666 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
March 09, 2022 Filed Mar 9, 2022 21:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 SaleCommon Stock 4,083 $3.33 $13,596.39
Disclosure

SEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · nonDerivative · entry 2

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 876,041

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Reporting person intends to use the proceeds of this sale to pay taxes resulting from the recent vesting of Restricted Stock Units granted by the issuer.

Read SEC document
March 08, 2022 Filed Mar 9, 2022 21:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionRestricted Stock Unit · Derivative 11,666 $0.00 $0.00
Disclosure

SEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
March 08, 2022 Filed Mar 9, 2022 21:05 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 Exercise / conversionCommon Stock 11,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001055726-22-000014 · wf-form4_164685990756495.xml · nonDerivative · entry 1

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880,124

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares vested on March 8, 2020; 11,667 shares vested on March 8, 2021; 11,666 shares vested on March 8, 2022. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2022 Filed Mar 1, 2022 23:51 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantRestricted Stock Unit · Derivative 35,000 $0.00 $0.00
Disclosure

SEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · derivative · entry 4

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F3 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 35,000 restricted stock units is as follows: 11,667 shares will vest on February 26, 2023; 11,667 shares will vest on February 26, 2024; 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Read SEC document
February 26, 2022 Filed Mar 1, 2022 23:51 UTC INOVIO PHARMACEUTICALS, INC. INO · Entity 6589 GrantCommon Stock Option · Derivative 60,000 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0001055726-22-000013 · wf-form4_164617866156651.xml · derivative · entry 3

Weiner David B. · CIK 0001669080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2032-02-26

F2 · derivative.exercise_date: The vesting schedule for the 60,000 options is as follows: 15,000 shares vested on February 26, 2022; 15,000 shares will vest on February 26, 2023; 15,000 shares will vest on February 26, 2024; 15,000 shares will vest on February 26, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.